The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...